Resources Repository
-
ArticlePublication 2021Racial and Ethnic Inequities in the Early Distribution of U.S. COVID-19 Testing Sites and Mortality
In 2020, U.S. COVID-19 testing sites were pivotal not just for diagnosis but also to …
In 2020, U.S. COVID-19 testing sites were pivotal not just for diagnosis but also to provide data that would contribute to understanding transmission. This research explored how these sites were distributed in relation to racial and ethnic demographics and its connection to observed disparities in COVID-19 outcomes. Data from mid-April to late May 2020 revealed that testing sites were not equally distributed among racial groups. Specifically, there was an overrepresentation of testing sites in areas…
Test Performance | Health Outcomes | North America | Policy/Regulation | Social Determinants | Infectious Diseases | Culture/Society | Health/Medicine | Science/Technology -
BookPublication 2016Cost-Effectiveness in Health and Medicine, 2nd Edition
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The …
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The Second Panel on Cost-Effectiveness in Health and Medicine included experts drawn from academia, healthcare administration, and government. The book offers advice for conducting analyses to improve the allocation of health resources, and is intended for economists, policy analysts, hospital executives, and students across health, business, and humanities disciplines. New components of this edition, include an in-depth review of the past 20…
Technology Assessment | Costing Methods | Health Outcomes | North America | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Global | Europe -
BookPublication 2016Cost-Effectiveness Analysis in Health: A Practical Approach, 3rd Edition
Cost-Effectiveness Analysis in Health provides an introduction to the tools, methods, and procedures used to perform cost-effectiveness research. …
Cost-Effectiveness Analysis in Health provides an introduction to the tools, methods, and procedures used to perform cost-effectiveness research. This third edition contains new discussion on meta-analysis and advanced modeling techniques, a worked example using visual modeling software TreeAge Pro, and updated recommendations from the U.S. Public Health Service's Panel on Cost-Effectiveness in Health and Medicine. The book provides process-specific instruction in a concise, structured format to highlight common methods and techniques for: 1) Developing a thoroughly fleshed-out research project; 2) Working…
Technology Assessment | Costing Methods | Health Outcomes | North America | Policy/Regulation | Preferences/Values | Evidence Synthesis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Costing Methods | Health Outcomes | Value of Information | North America | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Evidence Synthesis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Benefit-Cost Analysis | Value of Information | North America | Policy/Regulation | State-Transition | Infectious Diseases | Economics/Finance | Europe -
ArticlePublication 2019Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity
This analysis estimates state-specific and demographic subgroup-specific trends and projections of the prevalence of categories …
This analysis estimates state-specific and demographic subgroup-specific trends and projections of the prevalence of categories of body-mass index (BMI) in the United States. Self-reported BMI from the Behavioral Risk Factor Surveillance System Survey (1993-1994 and 1999-2016) were obtained and corrected for quantile-specific self-reporting bias. Multinomial regressions were then fitted for each state and subgroup to estimate the prevalence of four BMI categories from 1990 through 2030: underweight or normal weight (BMI <25), overweight (25 to…
Calibration/Validation | Health Outcomes | North America | Social Determinants | Mathematical Models | Chronic Disease/Risk -
ArticlePublication 2022Excess Mortality and Elevated Body Weight in the U.S.
This analysis estimates excess mortality associated with elevated body weight in the United States by …
This analysis estimates excess mortality associated with elevated body weight in the United States by state and demographic subgroup. The authors developed a nationally-representative microsimulation (individual-level) model of US adults between 1999 and 2016, based on risk factor data from the Behavioral Risk Factor Surveillance System and body-mass index (BMI) mortality hazard ratios from a global pooling dataset. The model was calibrated to empirical all-cause mortality rates from CDC WONDER by state and subgroup, and…
Calibration/Validation | Health Outcomes | North America | Social Determinants | Microsimulation | Chronic Disease/Risk -
ArticlePublication 2021Individual and Social Determinants of COVID-19 Vaccine Uptake
This article examined the individual, communication and social determinants associated with COVID-19 vaccine uptake using …
This article examined the individual, communication and social determinants associated with COVID-19 vaccine uptake using national survey data collected before vaccines were available in the U.S. Of note, individuals under the federal poverty level and racial and ethnic minorities were oversampled. Outcomes included the likelihood of vaccinating self and dependents (e.g., children). Independent variables included perceptions of risk, exposure to different media for COVID-19 news, political party identification, confidence in scientists and social determinants of…
Health Outcomes | North America | Policy/Regulation | Social Determinants | Evidence Synthesis | Infectious Diseases | Clinical Care | Culture/Society | Health/Medicine | Science/Technology -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Test Performance | Technology Assessment | North America | Policy/Regulation | Probability/Bayes | Infectious Diseases | Health Systems | Government/Law | Health/Medicine | Global